Статті в журналах: "Heart involvement"

1

Lorenzoni, R. "Cardiac involvement in idiopathic hypereosinophilic syndrome." Heart 87, no. 6 (June 1, 2002): 553. http://dx.doi.org/10.1136/heart.87.6.553.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

NAKAYAMA, Y. "Echocardiographic features of cardiac involvement in Fabry's disease." Heart 83, no. 6 (June 1, 2000): 695. http://dx.doi.org/10.1136/heart.83.6.695.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Marupakula, Vidyasagargoud, Karyne L. Vinales, Mohammad Q. Najib, Louis A. Lanza, Howard R. Lee, and Hari P. Chaliki. "Occurrence of left-sided heart valve involvement before right-sided heart valve involvement in carcinoid heart disease." European Heart Journal - Cardiovascular Imaging 12, no. 3 (December 17, 2010): E18. http://dx.doi.org/10.1093/ejechocard/jeq171.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

4

Doehner, Wolfram. "Mental involvement in heart failure." Revista Portuguesa de Cardiologia 40, no. 8 (August 2021): 557–59. http://dx.doi.org/10.1016/j.repc.2021.04.003.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Doehner, Wolfram. "Mental involvement in heart failure." Revista Portuguesa de Cardiologia (English Edition) 40, no. 8 (August 2021): 557–59. http://dx.doi.org/10.1016/j.repce.2021.07.026.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Šerpytis, Pranas, Žaneta Petrulionienė, Urtė Gargalskaitė, Aurelija Gedminaitė, and Violeta Panavienė. "Heart Involvement in Kawasaki Disease." Sveikatos mokslai 24, no. 3 (August 14, 2014): 27–32. http://dx.doi.org/10.5200/sm-hs.2014.039.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Ferri, C., D. Giuggioli, M. Sebastiani, M. Colaci, and M. Emdin. "Heart involvement and systemic sclerosis." Lupus 14, no. 9 (September 2005): 702–7. http://dx.doi.org/10.1191/0961203305lu2204oa.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

8

Azevedo, E. M., M. Scaff, E. R. Barbosa, A. E. Gouveia Neto, and H. M. Canelas. "Heart involvement in hepatolenticular degeneration." Acta Neurologica Scandinavica 58, no. 5 (January 29, 2009): 296–303. http://dx.doi.org/10.1111/j.1600-0404.1978.tb02890.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Clements, Philip J., and Daniel E. Furst. "Heart involvement in systemic sclerosis." Clinics in Dermatology 12, no. 2 (April 1994): 267–75. http://dx.doi.org/10.1016/s0738-081x(94)90331-x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Koju, Rajendra, R. Gurung, P. Pant, B. Pokharel, and TRS Bedi. "Pattern of Heart Valve Involvement in Rheumatic Heart Disease." Nepalese Heart Journal 6, no. 1 (November 24, 2017): 17–22. http://dx.doi.org/10.3126/njh.v6i1.18449.

Повний текст джерела

Анотація:

Rheumatic heart disease is the most important consequence of acute rheumatic fever. Both are common cardiovascular problems in Nepal. Echocardiographic detection of rheumatic heart disease is important to establish the diagnosis. The involvement of valves and their severity guides the therapeutic options. A total of 133 valvular heart disease cases attended in Dhulikhel Hospital between July 2008 to June 2009 were analyzed. Fifty-one patients, in whom the problems were rheumatic in origin were studied. Among them, 12% (6) had isolated aortic valve involvement, 35%(18) had isolated mitral valve and 53%(27) ahd mixed involvement. Severe mitral stenosis accounts for 24% of all mitral stenosis and severe aortic stenosis is 20% fo all aortic stenosis. The rates for severe mitral regurgitation and severe aortic regurgitaiton are 30% and 28% respectively. Although the study population has a high number of female patients, the differences in the rates of involvement of aortic or mitral valve in both genders are statistically insignificant. The study, although small, confirms that in this population, females are more commonly affected, that the mitral valve is the most commonly damaged valve and that disease affecting multiple valves is marginally more common than isolated valve disease. The detection of valvular involvement at different stages can guide the therapeutic options.

Стилі APA, Harvard, Vancouver, ISO та ін.

11

Allanore, Yannick, and Andre Kahan. "Primary Heart Involvement in Systemic Sclerosis." Current Rheumatology Reviews 2, no. 3 (August 1, 2006): 245–49. http://dx.doi.org/10.2174/157339706778019593.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Shkala, Lyubov. "Heart Involvement in Diabetes mellitus Patients." Family Medicine, no. 1-2 (April 29, 2022): 81–84. http://dx.doi.org/10.30841/2307-5112.1-2.2022.260509.

Повний текст джерела

Анотація:

Diabetes mellitus (DM) is one of the most significant medical and social health problems worldwide. The main cause of death in patients with DM is cardiovascular diseases, which leads to the significant decrease in quality of life and life expectancy. The aim of this literature review is analyze of the frequency, mechanisms and manifestations of heart disease in diabetes patients. A significant amount of the modern researches is devoted to the diagnosis and treatment of the diabetes complications, including diabetic cardiomyopathy (DC). According to many authors, heart disease in diabetes is associated with the formation of DC, comorbid coronary heart disease and arterial hypertension. DC occurs in 16.8–54% of patients with diabetes and is an independent factor which increases the death risk by 50–60%. Numerous scientific studies have been devoted to the diagnosis and treatment of DC, emphasizing that in order to reduce cardiovascular disease and mortality in patients with diabetes, it is necessary, above all, to achieve glycemic control. Diabetic history, age, comorbidities, atherosclerotic lesions, smoking, overweight or obesity also play an important role. The main aspects of the development and impact of diabetes on the health and life of patients are the untimely diagnosis of this disease, its multifactorial pathogenesis, progressive course and severity of complications. Due to development of the early complications and disability, studies of morphofunctional changes in the myocardium in diabetes are extremely relevant, as cardiomyopathy may increase the risk of myocardial infarction and heart failure. The rapid increase in the number of patients with diabetes, many of whom die from cardiovascular complications, makes the problem of diabetic heart disease one of the most pressing health problems. Treatment of these patients should include correction of carbohydrate metabolism, control of blood lipid composition, decrease in myocardial ischemia, correction of the myocardial metabolism and the risk of heart failure.

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Fong, Brandon, and Laura Vearrier. "STEMI with right ventricular heart involvement." Visual Journal of Emergency Medicine 8 (July 2017): 113–14. http://dx.doi.org/10.1016/j.visj.2017.01.015.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Weidemann, Frank, Joerg M. Strotmann, Markus Niemann, Sebastian Herrmann, Mario Wilke, Meinrad Beer, Wolfram Voelker, et al. "Heart Valve Involvement in Fabry Cardiomyopathy." Ultrasound in Medicine & Biology 35, no. 5 (May 2009): 730–35. http://dx.doi.org/10.1016/j.ultrasmedbio.2008.10.010.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

JANCIN, BRUCE. "Heart Involvement Missed In Systemic Sclerosis." Rheumatology News 10, no. 4 (April 2011): 16–17. http://dx.doi.org/10.1016/s1541-9800(11)70245-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

JANCIN, BRUCE. "Heart Involvement in Systemic Sclerosis Underappreciated." Skin & Allergy News 42, no. 5 (May 2011): 48. http://dx.doi.org/10.1016/s0037-6337(11)70291-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

JANCIN, BRUCE. "Heart Involvement in Systemic Sclerosis Underappreciated." Internal Medicine News 44, no. 6 (April 2011): 12. http://dx.doi.org/10.1016/s1097-8690(11)70273-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Vogl, T. J., H. Schmidt, and L. Porto. "Interstitial involvement in children: "shaggy heart"." European Radiology 14, no. 3 (March 1, 2004): 534–36. http://dx.doi.org/10.1007/s00330-003-1903-y.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

TöRNEBRANDT, K., J. Eskilsson, and A. Nobin. "Heart involvement in metastatic carcinoid disease." Clinical Cardiology 9, no. 1 (January 1986): 13–19. http://dx.doi.org/10.1002/clc.4960090104.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

JANCIN, BRUCE. "Heart Involvement Missed in Systemic Sclerosis." Cardiology News 9, no. 6 (June 2011): 22. http://dx.doi.org/10.1016/s1544-8800(11)70183-x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Brunger, A. F., J. Bijzet, H. Blokzijl, R. Van Rheenen, R. Gans, B. Hazenberg, and H. L. A. Nienhuis. "POS0124 DIAGNOSTIC VALUE OF LIVER STIFFNESS AS MARKER OF HEPATIC MARKER OF HEPATIC AMYLOID DEPOSITION IN SYSTEMIC AL AMYLOIDOSIS." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 287.2–288. http://dx.doi.org/10.1136/annrheumdis-2022-eular.4347.

Повний текст джерела

Анотація:

BackgroundHepatic involvement in AL amyloidosis is often asymptomatic but does affect prognosis and should be taken into account during follow-up. An increased plasma level of alkaline phosphatase (ALP) or increased liver span are part of the conventional diagnostic criteria for establishing hepatic involvement1, however these markers are nonspecific. 123I-labeled serum amyloid P component (SAP) scintigraphy is a specific and sensitive method to establish hepatic involvement but is not widely available. Liver stiffness measured by transient elastography is increased in AL amyloidosis patients with hepatic involvement and could be useful in establishing liver involvement and monitoring treatment response in AL-amyloidosis.ObjectivesTo assess the diagnostic value of liver stiffness (LS) for liver involvement in AL amyloidosis and the utility of LS to monitor treatment effect using SAP scintigraphy as gold standard.MethodsLS was measured prospectively in 49 treatment naive patients with systemic AL amyloidosis and 9 patients with wild type transthyretin amyloidosis (ATTRwt) with cardiomyopathy (cardiac controls). In addition, LS was longitudinally measured in 10 AL amyloidosis patients of whom 9 patients had liver involvement. SAP scintigraphy, laboratory assessments including ALP and measurement of liver span was performed in all patients.ResultsOf the 49 patients, 27 patients had liver involvement (of whom 24 also had heart involvement), 10 patients had heart involvement, 12 patients had no heart or liver involvement. Median LS was significantly higher in AL amyloidosis patients with liver involvement (22.8 kPa, range 4.3-75), than in AL amyloidosis patients without liver involvement (6.3 kPa, range 4.4-35.8) (p=0.000). Also a significant difference was seen between AL amyloidosis patients with liver involvement (22.8.9, range 4.3-75) versus, heart involvement (9.0, range 4.5-35.8) (p=0.02), no liver or heart involvement (5.7, range 4.4-10.1) (p=0.0001), and ATTRwt patients (9.9 kPa, range 4.0-14.6) (p=0.01). Furthermore, LS values seemed to significantly decrease over time in AL amyloidosis patients with liver involvement with a good hematologic response to treatment.ConclusionLS is a non-invasive tool which seems to be useful in clinical practice to establish liver involvement in patients with AL amyloidosis. In addition, it is a promising marker in the follow up of AL amyloidosis patients for establishing hepatic response over time.References[1]Gertz et al. Am J Hematol 2005;79319-328Disclosure of InterestsNone declared

Стилі APA, Harvard, Vancouver, ISO та ін.

22

MILLWARD, M. J., M. P. BLAKE, J. HUNG, P. GIBSON, and M. J. BYRNE. "LEFT HEART INVOLVEMENT WITH CARDIAC SHUNT COMPLICATING CARCINOID HEART DISEASE." Australian and New Zealand Journal of Medicine 19, no. 6 (December 1989): 716–17. http://dx.doi.org/10.1111/j.1445-5994.1989.tb00343.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Akhmedov, V. A., I. A. Sezina, A. N. Kuzovkin, and A. N. Keruchenko. "Metastatic heart involvement as lung carcinoma complication." Russian Pulmonology, no. 5 (January 1, 2013): 101–2. http://dx.doi.org/10.18093/0869-0189-2013-0-5-101-102.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Salzano, Andrea, Shabana Cassambai, Yoshiyuki Yazaki, Muhammad Zubair Israr, Dennis Bernieh, Max Wong, and Toru Suzuki. "The Gut Axis Involvement in Heart Failure." Cardiology Clinics 40, no. 2 (May 2022): 161–69. http://dx.doi.org/10.1016/j.ccl.2021.12.004.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Gadaev, Igor Y., V. I. Ershov, O. V. Bochkarnikova, I. Ya Sokolova, D. A. Budanova, E. S. Kotova, and A. S. Lishuta. "Extranodal involvement of the heart in lymphomas." Clinical Medicine (Russian Journal) 94, no. 10 (November 24, 2016): 780–84. http://dx.doi.org/10.18821/0023-2149-2016-94-10-780-784.

Повний текст джерела

Анотація:

The authors report a case of rare cardiac involvement in lymphoma, one of the manifestations of which was rhythm and conduction disorders with their resolution after chemotherapy. Also presented are clinical manifestations of heart lesions in lymphoma and modern methods of their diagnostics and treatment.

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Patel, Mita B., Victor Mor-Avi, Gillian Murtagh, Catherine A. Bonham, Luke J. Laffin, Douglas Kyle Hogarth, Diego Medvedofsky, Roberto M. Lang, and Amit R. Patel. "Right Heart Involvement in Patients with Sarcoidosis." Echocardiography 33, no. 5 (January 16, 2016): 734–41. http://dx.doi.org/10.1111/echo.13163.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

SAMUELSSON, OLA, JOHN WIKSTRAND, LARS WILHELMSEN, and GÖRAN BERGLUND. "Heart and Kidney Involvement during Antihypertensive Treatment." Acta Medica Scandinavica 215, no. 4 (April 24, 2009): 305–11. http://dx.doi.org/10.1111/j.0954-6820.1984.tb05012.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Erdoes, Luke S., and Glenn C. Hunter. "Peripheral Vascular Involvement in Heart Transplant Patients." Annals of Vascular Surgery 8, no. 6 (November 1994): 611. http://dx.doi.org/10.1007/bf02017422.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

29

Julia, Pierre, Catherine Amrein, Balkis Ghalayini, Victor Jebara, Romain Guillemain, Isabelle Roussin, Alain Carpentier, and Jean-Noel Fabiani. "Peripheral Vascular Involvement in Heart Transplant Patients." Annals of Vascular Surgery 8, no. 3 (May 1994): 266–70. http://dx.doi.org/10.1007/bf02018174.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

Salzano, Andrea, Shabana Cassambai, Yoshiyuki Yazaki, Muhammad Zubair Israr, Dennis Bernieh, Max Wong, and Toru Suzuki. "The Gut Axis Involvement in Heart Failure." Heart Failure Clinics 16, no. 1 (January 2020): 23–31. http://dx.doi.org/10.1016/j.hfc.2019.08.001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Briggs, Patricia E. "Improved Heart Failure Outcomes through Family Involvement." Journal of Cardiac Failure 17, no. 8 (August 2011): S79. http://dx.doi.org/10.1016/j.cardfail.2011.06.266.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Loeb, J. M., J. M. deTarnowsky, M. R. Warner, and C. C. Whitson. "Postpacing tachycardia: autonomic involvement." American Journal of Physiology-Heart and Circulatory Physiology 253, no. 2 (August 1, 1987): H333—H340. http://dx.doi.org/10.1152/ajpheart.1987.253.2.h333.

Повний текст джерела

Анотація:

The cessation of pacing from the sinus node region is followed by a transient sinus tachycardia or postpacing tachycardia (PPT). We sought to characterize autonomic involvement in PPT. We used alpha-chloralose-anesthetized dogs and recorded electrocardiograms, blood pressure, and electrograms from the sinus node, right atrium, right ventricle, and His bundle. Both vagi and both stellate ganglia were transected. PPT developed immediately after either linear or stepped heart rate changes. PPT followed pacing from the rostral but not the caudal region of the sulcus terminalis. Independent manipulation of absolute level of heart rate (+33, +66, and +100 beats/min above control) and duration of atrial pacing (10, 20, and 30 s) revealed that PPT is dependent predominantly on the duration of pacing and less on level of heart rate. During pacing in the control state, a 1:1 atrial capture was maintained. After atropine administration (0.2 mg/kg iv), PPT increased significantly in magnitude, time to peak PPT was shortened significantly, and loss of 1:1 atrial capture during pacing was evident at pacing rates of from 10 to 60 beats above control. In contrast, propranolol significantly attenuated PPT. We conclude that acetylcholine, released during pacing from the sinus node region, suppresses inherent sinus node acceleration induced by the concurrent release of intramural catecholamines. During pacing, acetylcholine release is essential for the maintenance of 1:1 atrial capture and significantly modulates both the latency and magnitude of PPT.

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Li, Jing, Hongchao Li, Fei Sun, Zhe Chen, Yunjiao Yang, Jiuliang Zhao, Mengtao Li, Xinping Tian, and Xiaofeng Zeng. "Clinical Characteristics of Heart Involvement in Chinese Patients with Takayasu Arteritis." Journal of Rheumatology 44, no. 12 (August 15, 2017): 1867–74. http://dx.doi.org/10.3899/jrheum.161514.

Повний текст джерела

Анотація:

Objective.To understand the characteristics of heart involvement in Chinese patients with Takayasu arteritis (TA).Methods.The medical charts of 411 patients with TA (325 women, 86 men) were retrospectively reviewed. The comparison of clinical manifestations was carried out between the patients with TA with (n = 164) and without (n = 247) heart involvement.Results.The median age at disease onset was 23.0 years (18.0–30.0) in 411 patients with TA, and 23.0 years (17.3–30.0) in 164 patients with heart involvement. The disease duration of the heart involvement group (median: 24.0 mos) was significantly longer than those patients without heart involvement (the control group, median: 16.0 mos). Hypertension (57.3% vs 46.6%; p = 0.033), renal dysfunction (17.1% vs 7.7%; p = 0.003), and bruit in the subclavian artery (45.1% vs 34.4%; p = 0.029) were more common in the heart involvement group than patients without. Valvular abnormalities were found in 134 (81.7%) patients in the heart involvement group, myocardial abnormalities in 26 (15.9%), and coronary artery abnormalities in 19 patients (11.6%). The age at onset (yrs) and disease duration (mos) of patients with myocardial, valvular, and coronary arterial abnormalities were 18.8/13.0, 23.8/23.5, and 26.8/57.0, respectively. In the heart involvement group, 22 patients (84.6%) with myocardial abnormalities, 15 (78.9%) with coronary arterial abnormalities, and 89 (66.4%) with valvular abnormalities had Numano type V vessel involvement. The level of high-sensitivity C-reactive protein was higher in the heart involvement group (median: 10.0 mg/l), and the difference was significant when compared to the control group (median: 7.0 mg/l; p = 0.017).Conclusion.Patients with TA complicated with cardiac abnormalities are not rare, especially in patients with Numano type V vessel involvement. We suggest that echocardiogram screening may be a helpful tool to understand the whole feature of patients with TA.

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Sugraliyev, A. B. "Cardiac Involvement in COVID-19." Kardiologiia 61, no. 4 (May 6, 2021): 15–23. http://dx.doi.org/10.18087/cardio.2021.4.n1408.

Повний текст джерела

Анотація:

The novel coronavirus infection, COVID-19, is a highly contagious viral disease associated with acute, severe respiratory syndrome, which is based on the development of pronounced thrombo-inflammatory syndrome. As the number of patients with COVID-19 increased, heart damage has been reported, especially in patients with severe and critical COVID-19. This review describes the role of angiotensin-converting enzyme 2 receptor in the regulation of viral entry, the variety of damages to the heart and coronary arteries, and the importance of arterial hypertension and of the use of renin-angiotensin-aldosterone system inhibitors in the prognosis of patients with COVID-19.

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Killu, Ammar M., Darrell B. Newman, William R. Miranda, Joseph J. Maleszewski, Patricia Pellikka, Hartzell V. Schaff, and Heidi M. Connolly. "Carcinoid Heart Disease without Severe Tricuspid Valve Involvement." Cardiology 133, no. 4 (December 15, 2015): 217–22. http://dx.doi.org/10.1159/000441488.

Повний текст джерела

Анотація:

Carcinoid syndrome causes a rare form of acquired valvular heart disease which typically occurs in the setting of liver metastases. In carcinoid-induced valvular heart disease, the tricuspid valve is almost universally affected; left-sided valve disease occurs infrequently in affected patients. Herein, we report 2 cases of carcinoid-induced valvular heart disease; one case had no evidence of tricuspid valve involvement despite severe involvement of all other valves, while the other case was without severe tricuspid valve involvement.

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Hidron, Alicia, Nicholas Vogenthaler, José I. Santos-Preciado, Alfonso J. Rodriguez-Morales, Carlos Franco-Paredes, and Anis Rassi. "Cardiac Involvement with Parasitic Infections." Clinical Microbiology Reviews 23, no. 2 (April 2010): 324–49. http://dx.doi.org/10.1128/cmr.00054-09.

Повний текст джерела

Анотація:

SUMMARY Parasitic infections previously seen only in developing tropical settings can be currently diagnosed worldwide due to travel and population migration. Some parasites may directly or indirectly affect various anatomical structures of the heart, with infections manifested as myocarditis, pericarditis, pancarditis, or pulmonary hypertension. Thus, it has become quite relevant for clinicians in developed settings to consider parasitic infections in the differential diagnosis of myocardial and pericardial disease anywhere around the globe. Chagas' disease is by far the most important parasitic infection of the heart and one that it is currently considered a global parasitic infection due to the growing migration of populations from areas where these infections are highly endemic to settings where they are not endemic. Current advances in the treatment of African trypanosomiasis offer hope to prevent not only the neurological complications but also the frequently identified cardiac manifestations of this life-threatening parasitic infection. The lack of effective vaccines, optimal chemoprophylaxis, or evidence-based pharmacological therapies to control many of the parasitic diseases of the heart, in particular Chagas' disease, makes this disease one of the most important public health challenges of our time.

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Lee, S. J. "HLA-B27 positive juvenile arthritis with cardiac involvement preceding sacroiliac joint changes." Heart 86, no. 6 (December 1, 2001): 19e—19. http://dx.doi.org/10.1136/heart.86.6.e19.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Patwary, Mohammad Saifullah, KMHS Sirajul Haque, Nusrat Shoaib, Khondaker Syedus Salehin, and ATM Iqbal Hosan. "Cardiac Involvement of Hepatitis B and C Virus Infection." University Heart Journal 8, no. 2 (August 5, 2013): 113–18. http://dx.doi.org/10.3329/uhj.v8i2.16084.

Повний текст джерела

Анотація:

Hepatitis B virus (HBV) and Hepatitis C virus (HCV) are the cause of many different forms of heart disease worldwide and yet few cardiologists are aware of it as an etiology of heart disease, or its treatment. The burden of HBV and HCV derived heart diseases are global, with a higher prevalence in Asia, Africa, and low- and middle-income countries. The study showed that in more than 10% of Japanese patients, their cardiomyopathies are associated with HCV infection. More recently, it is found in the USA that up to 15% of patients with heart failure with myocarditis have been associated HCV infection. In contrast, in China 79% of patients with hepatocellular cancer and 37% of hepatitis C patients have heart disease, as detected by measuring a proven and sensitive biomarker of heart disease, NT-proBNP. In Pakistan, 17% of hepatitis C patients have heart diseases, as measured by this metric (NT-proBNP). Based on these data, 3% of 6.6 billion (198 million) persons worldwide are infected with HCV and 1737% (3473 million) persons are suffering from HCV-derived heart diseases. These figures may be comparable to the number of patients with hepatitis C. HCV infection causes only hepatitis in some patients, only heart diseases in some patients, and both hepatitis and heart diseases in other patients. A global network is required to establish methods to detect heart diseases caused by infectious agents. Other goals for the network are the expansion of preventive and therapeutic programs in under privileged countries. DOI: http://dx.doi.org/10.3329/uhj.v8i2.16084 University Heart Journal Vol. 8, No. 2, July 2012

Стилі APA, Harvard, Vancouver, ISO та ін.

39

Stamouli, Maria, Konstantinos Gkirkas, Aiantas Antoniades, Loukas Kaklamanis, Konstantinos Gkodopoulos, John Palios, Angeliki Karagiannidou, George Makavos, Ignatios Ikonomidis, and Panagiotis Tsirigotis. "Isolated extramedullary leukemic involvement of the heart presenting as fulminant heart failure." Annals of Hematology 98, no. 7 (March 11, 2019): 1775–76. http://dx.doi.org/10.1007/s00277-019-03665-3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Cotella, Juan I., Ana L. Sauce, Clara I. Saldarriaga, Gonzalo E. Perez, Juan M. Farina, Fernando Wyss, Alvaro Sosa Liprandi, et al. "Chikungunya and the Heart." Cardiology 146, no. 3 (2021): 324–34. http://dx.doi.org/10.1159/000514206.

Повний текст джерела

Анотація:

Introduction: Neglected tropical diseases are a group of communicable diseases that occur in tropical and subtropical conditions and are closely related to poverty and inadequate sanitation conditions. Among these entities, chikungunya remains one of the most widely spread diseases. Although the main symptoms are related to a febrile syndrome, cardiovascular (CV) involvement has been reported, with short- and long-term implications. As part of the “Neglected Tropical Diseases and other Infectious Diseases involving the Heart” (NET-Heart) Project, the aim of this review is to compile all the information available regarding CV involvement of this disease, to help healthcare providers gain knowledge in this field, and contribute to improving early diagnosis, treatment, and prevention strategies. Methods: We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement in conducting and reporting this systematic review. The search was conducted using MEDLINE/PubMed, SciELO, and LILACS databases to identify any relevant studies or reviews detailing an association between chikungunya and cardiac involvement published from January 1972 to May 31, 2020. Results: Despite its mechanism not being fully understood, CV involvement has been described as the most frequent atypical presentation of chikungunya (54.2%). Myocarditis is the most prevalent CV complication. Different rhythm disturbances have been reported in 52% of cases, whereas heart failure was reported in 15% of cases, pericarditis in 5%, and acute myocardial infarction in 2%. Overall estimated CV mortality is 10%, although in patients with other comorbidities, it may increase up to 20%. In the proper clinical setting, the presence of fever, polyarthralgia, and new-onset arrhythmia suggests chikungunya virus-related myocarditis. Conclusion: Although most cases are rarely fatal, CV involvement in chikungunya infection remains the most frequent atypical presentation of this disease and may have severe manifestations. Timely diagnosis and appropriate management are necessary to improve patient outcomes.

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Castro, José Luis, Daniel Ricci, Carlos Alberto Taira, and Agustín Ramirez. "Central benzodiazepine involvement in clonidine cardiovascular actions." Canadian Journal of Physiology and Pharmacology 77, no. 11 (October 25, 1999): 844–51. http://dx.doi.org/10.1139/y99-086.

Повний текст джерела

Анотація:

It is well known that the GABAergic and noradrenergic systems play an important role in blood pressure and heart rate regulation. Benzodiazepines and beta-carbolines, respectively, increase or decrease the probability of chloride-channel opening induced by GABA. The aim of this study was to determine, in conscious rats, the interaction existing between the central alpha2-adrenoceptor stimulation induced by clonidine and the facilitation or impairment of benzodiazepine receptor activity through the administration of either diazepam, a benzodiazepine receptor agonist, or methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM), an inverse benzodiazepine agonist. Clonidine (5-10 µg, intracerebroventricularly) reduced heart rate and increased mean blood pressure by activation of central alpha2-adrenoceptors. Diazepam (2 mg/kg, intravenously (i.v.)) induced an increase in heart rate, while DMCM (0.3 mg/kg, i.v.) elicited a bradycardic effect. The bradycardic effects induced by both clonidine and DMCM were antagonized by the prior administration of methylatropine (1.5 mg/kg, i.v.). DMCM (0.3 mg/kg, i.v.) prevented the clonidine effects on heart rate and mean blood pressure, while diazepam (2 mg/kg, i.v.) failed to modify these effects. Our results suggest that the bradycardic effects of clonidine are mediated by a vagal stimulation and are related to the activation of a GABAergic pathway.Key words: blood pressure, clonidine, diazepam, methyl 6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM), heart rate.

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Zuilma Yurith, Vásquez-Ortiz. "Extensive Intravascular Leiomyomatosis with Cardiac Involvement, Clinicopathological and Imaging Characteristics: A Case Report." Clinical Cardiology and Cardiovascular Interventions 5, no. 7 (August 8, 2022): 01–04. http://dx.doi.org/10.31579/2641-0419/266.

Повний текст джерела

Анотація:

Intracardiac masses are a rare differential diagnosis in patients who present heart failure symptoms, these are classified by many authors as neoplastic or non-neoplastic, dependent or not on the heart chambers. Being able to differentiate and classify intracardiac masses is very important because treatment and prognosis depend on it. Intravascular leiomyomatosis is one of the rarest tumors, characterized by direct overgrowth of a uterine leiomyoma through adjacent veins with an unusual growth pattern. To date, less than 300 cases have been reported, with proliferation to the heart chambers being even rarer. We present the case of a female who presented to the emergency department due to dyspnea and palpitations, during his approach, a mass from the inferior vena cava was found causing intermittent tricuspid obstruction. Later it was documented as coming directly from the uterus, diagnosing intravascular leiomyoma by pathology.

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Lou, H., I. Danelisen, and P. K. Singal. "Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy." American Journal of Physiology-Heart and Circulatory Physiology 288, no. 4 (April 2005): H1925—H1930. http://dx.doi.org/10.1152/ajpheart.01054.2004.

Повний текст джерела

Анотація:

The current study investigated the phosphorylation of mitogen-activated protein kinases (MAPKs) as well as pro- and anti-apoptotic proteins in adriamycin (ADR)-induced cardiomyopathy (AIC) and heart failure in rats. Modulatory effects of antioxidant probucol on the activation of MAPKs were also examined. Male rats were administered with ADR (15 mg/kg body wt ip, over 2 wk) with and without probucol (120 mg/kg body wt for 4 wk ip). Hearts from these animals were studied at 1- to 24-h as well as at 3-wk posttreatment durations. In the 3-wk group, ADR depressed cardiac function, increased left ventricular end-diastolic pressure (LVEDP), and caused dyspnea and mortality. These changes were prevented by probucol. Phosphorylation of extracellular signal-regulated kinase (ERK)1/2, in the early stage of AIC, showed a biphasic response, with a maximum increase to 513% seen at 4 h, followed by a decrease to 66.8% at 3 wk after the last injection of ADR. Phosphorylation of p38 and c-Jun NH2-terminal kinases (JNKs) showed a steady increase through 2, 4, and 24 h and 3 wk (116% to 148%). In gene microarray analysis at 3 wk (heart failure stage), mRNA expression for both ERK1/2 and p38 kinases was decreased, whereas JNK mRNA was undetectable. Probucol completely prevented these MAPK changes. Activation of caspase-3 as well as the increase in the ratio of Bax to Bcl-xl were seen at early time points (1–24 h) as well as in the heart failure stage (3 wk). It is suggested that a transient increase in ERK1/2 at a shorter interval indicate an early adaptive response, and failure of this response corresponded with heart failure. In contrast, a gradual and persistent increase in p38 and JNK MAPKs as well as in caspase-3 and the Bax-to-Bcl-xl ratio may contribute in the initiation of apoptosis and progression of heart failure. Because probucol modulated changes in cellular signaling pathways and cardiac function, it is likely that oxidative stress plays a key role in AIC and heart failure.

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Sousa, Anastácio de Queiroz, F. Roberto Neves Solon, J. Eloy da Costa Filho, and F. Heli Cavalcante Lima. "Disseminated cysticercosis with asymptomatic involvement of the heart." Brazilian Journal of Infectious Diseases 10, no. 1 (February 2006): 65. http://dx.doi.org/10.1590/s1413-86702006000100014.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

D'CRUZ, IVAN A. "Right Heart Ischemic Involvement TEE-Dobutamine Stress Assessment." Echocardiography 15, no. 2 (February 1998): 169–70. http://dx.doi.org/10.1111/j.1540-8175.1998.tb00594.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Vereckei, András, Ádám Fazakas, Timea Baló, Béla Fekete, Mária Judit Molnár, and István Karádi. "Chloroquine cardiotoxicity mimicking connective tissue disease heart involvement." Immunopharmacology and Immunotoxicology 35, no. 2 (February 15, 2013): 304–6. http://dx.doi.org/10.3109/08923973.2013.766801.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Hartford, Marianne, Susanne Ljungman, Ove Andersson, John Wikstrand, and Göran Berglund. "Heart and Kidney Involvement and Prognosis in Hypertension." Acta Medica Scandinavica 205, no. 1-6 (April 24, 2009): 563–68. http://dx.doi.org/10.1111/j.0954-6820.1979.tb06104.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Eriksson, Anders, Bert-Ove Olofsson, and Peter Eriksson. "Heart valve involvement in familial amyloidosis with polyneuropathy." Pathology - Research and Practice 181, no. 5 (October 1986): 563–67. http://dx.doi.org/10.1016/s0344-0338(86)80150-9.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Wahbi, Karim, Guillaume Durand Viel, Rabah Ben Yaou, Anthony Behin, Henri-Marc Bécane, Pascal Laforet, Tanya Stojkovic, Bruno Eymard, Gisèle Bonne, and Denis Duboc. "0460: Right heart involvement in patients with laminopathies." Archives of Cardiovascular Diseases Supplements 8, no. 1 (January 2016): 26. http://dx.doi.org/10.1016/s1878-6480(16)30076-3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

Allanore, Y., C. Meune, and A. Kahan. "Outcome measures for heart involvement in systemic sclerosis." Rheumatology 47, Supplement 5 (October 1, 2008): v51—v53. http://dx.doi.org/10.1093/rheumatology/ken268.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Статті в журналах з теми "Heart involvement"

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями